Skip to main content

Table 4 Changes of the inflammatory and structural parameters between baseline and week 24

From: Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation—data from the prospective IVEPSA study

CharacteristicBaselineWeek 24p value
MRI
 PSAMRIS synovitis (median, IQR) (mean ± SD)1 (0, 2); 2.17 ± 4.611 (0, 2); 1.06 ± 1.960.008**
 PSAMRIS osteitis (median, IQR) (mean ± SD)0 (0, 0); 0.44 ± 1.890 (0, 0); 0.33 ± 1.410.317
 PSAMRIS periarticular (median, IQR) (mean ± SD)0 (0, 0); 0.28 ± 0.670 (0, 0); 0 ± 00.102
 PSAMRIS tenossynovitis (median, IQR) (mean ± SD)0 (0, 1); 0.61 ± 1.150 (0, 0); 0.33 ± 0.840.096
 PSAMRIS erosions (median, IQR)2 (0, 4)2 (0, 4)1.000
 PSAMRIS proliferation (median, IQR) (mean ± SD)0 (0, 1); 0.44 ± 0.710 (0, 1); 0.44 ± 0.861.000
 Total PSAMRIS (median, IQR)5 (1, 8)3 (0, 6)0.005**
HR-pQCT
 Erosion number (median, IQR)1 (0, 1.75)1 (0, 1.75)0.317
 Proliferation grade (median, IQR) (mean ± SD)0 (0, 1); 0.55 ± 0.760 (0, 2); 0.68 ± 0.890.180
 Dtot, HA/cm3 (median, IQR)303.1 (264.8, 320.8)308.9 (265.8, 324.9)0.020*
 Dtrab, HA/cm3 (median, IQR)165.2 (133.5, 205.7)165.7 (136.9, 206.9)0.048*
 Dcomp, HA/cm3 (median, IQR)840.5 (778.8, 848.3)831.1 (796.5, 854.8)0.184
 Bone stiffness, kN/mm (median, IQR)48.38 (38.58, 60.31)49.40 (38.14, 59.82)0.501
 Failure load, N (median, IQR)2312.2 (1862.6, 2817.0)2390.0 (1798.6, 2847.2)0.352
  1. Data are based on 18 psoriasis patients with complete baseline and 24-week data
  2. PSAMRIS psoriatic arthritis magnetic resonance imaging scoring system, MRI magnetic resonance imaging, HR-pQCT high-resolution peripheral quantitative computed tomography, IQR interquartile range, Dtot average bone density, HA hydroxyapatite, Dtrab trabecular bone density, Dcomp cortical bone density, N Newton
  3. Additionally reported as mean and standard deviation (mean ± SD) because median was equal to zero
  4. Wilcoxon signed-rank test. *p ≤ 0.05, **p ≤ 0.01